Compare BMHL & PMVP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BMHL | PMVP |
|---|---|---|
| Founded | 2016 | 2013 |
| Country | Hong Kong | United States |
| Employees | 9 | N/A |
| Industry | | Medicinal Chemicals and Botanical Products |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 93.9M | 79.5M |
| IPO Year | N/A | 2020 |
| Metric | BMHL | PMVP |
|---|---|---|
| Price | $3.33 | $1.31 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 1.6K | ★ 894.8K |
| Earning Date | 08-14-2026 | 03-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $66.66 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.72 | $0.82 |
| 52 Week High | $4.48 | $1.88 |
| Indicator | BMHL | PMVP |
|---|---|---|
| Relative Strength Index (RSI) | 46.53 | 41.81 |
| Support Level | $3.32 | $1.26 |
| Resistance Level | $3.89 | $1.50 |
| Average True Range (ATR) | 0.16 | 0.06 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 50.00 | 2.56 |
Bluemount Holdings Ltd through its operating subsidiaries, it is a Hong Kong-based consulting and advisory and financial services provider, as well as trader of commodities such as luxury timepieces. The financial services includes underwriting and placing services, securities dealing and brokerage services, and asset management services. It provides comprehensive consulting and advisory services on business development strategies to its diverse clientele. Generally, the company provides consulting and advisory business for the following segments: Corporate Finance; and Strategic Communications.
PMV Pharmaceuticals Inc is a precision oncology company. The company is engaged in the research and development of small molecule, tumor-agnostic therapies targeting p53 mutations, which can eliminate cancer cells. The key product candidate, rezatapopt, is designed to be an orally available small molecule that structurally corrects the mutant p53 protein with the Y220C mutation. Currently, the product candidates are undergoing preclinical and clinical testing, and company relies on third parties for the manufacture after marketing approvals.